American Biogenetic Sciences
This article was originally published in The Gray Sheet
Executive Summary
Cutting staff by 40%, from roughly 50 employees to 30. The cuts are part of a downsizing that will "enable the company to focus its intellectual and corporate resources" toward commercialization of its Solfib soluble fibrin test, MH-1 blood clot imaging agent, and FIPT fibrinogen test, the company says. ABS will also "put on hold" the development of diagnostic tests for Alzheimer's, epilepsy, and breast cancer